Florida’s RICO Gambit Targets Doctors’ Guidelines

Close-up of a dictionary entry for political action committee

When a state attorney general deploys consumer-fraud and racketeering statutes against a national medical society for publishing clinical guidelines, the legal system faces a question that goes well beyond any single dispute about pediatric care: can professional speech — the kind that shapes how doctors treat patients — be prosecuted as a deceptive trade practice?

At a Glance

Florida AG James Uthmeier sued the American Academy of Pediatrics, WPATH, and the Endocrine Society in December 2025, alleging their gender-affirming care guidelines constitute deceptive trade practices and RICO violations.
A federal district judge found the suit was initiated in bad faith, misrepresented AAP’s positions, and was designed to chill free speech — then issued a preliminary injunction halting it.
The Seventh Circuit Court of Appeals has since allowed the Florida state-court suit to proceed, reversing the injunction — meaning the litigation is live again, though the bad-faith findings remain on the record.
The case is part of a documented national pattern of states using consumer-protection and RICO laws as instruments against medical organizations that endorse gender-affirming care for minors.
The core legal question — whether clinical guideline-setting by a nonprofit medical society can constitute a “deceptive trade practice” — has not been definitively resolved and will shape medical free speech for years.

What Florida Actually Alleges

Filed in Florida state court on December 9, 2025, the complaint names three organizations simultaneously: the American Academy of Pediatrics (AAP), the World Professional Association for Transgender Health (WPATH), and the Endocrine Society. Florida Attorney General James Uthmeier invoked two legal theories — the Florida Deceptive and Unfair Trade Practices Act (FDUTPA) and the state’s Racketeer Influenced and Corrupt Organizations statute — to argue that these groups made false advertising claims to the medical profession and the public. The complaint’s specific factual allegations are narrow but pointed: that the defendants falsely advertised that gender-affirming interventions mitigate gender dysphoria and suicidality, that puberty blockers are fully reversible, and that their clinical guidelines are evidence-based.

The financial hook — required to sustain a consumer-protection claim — is the allegation that these organizations made misleading representations in order to gain financially from memberships and associated services. That framing matters legally: FDUTPA requires a commercial transaction or trade practice, and characterizing clinical guideline publication as a profit-generating commercial activity is a significant doctrinal stretch. The complaint roots the dispute in AAP’s 2018 policy statement “Ensuring Comprehensive Care and Support for Transgender and Gender-Diverse Children and Adolescents,” reaffirmed in 2023 — a document that has been freely and publicly accessible online throughout.

The Federal Courts Intervene — and Disagree

The AAP did not simply defend in Florida state court. In March 2026, it filed its own federal lawsuit in the Northern District of Illinois, arguing that Uthmeier’s action was retaliatory and an unconstitutional effort to suppress First Amendment-protected speech. U.S. District Judge Matthew Kennelly granted a preliminary injunction halting Florida’s state-court suit in June 2026 — and his ruling was notably sharp in its findings. Kennelly concluded that “the objective weakness of the state complaint and the more evidence of Uthmeier’s subjective bad faith combined create a mosaic of specific facts that support an inference of bad faith.” He also found that Uthmeier had seriously misrepresented AAP’s policy positions, and he cited the AG’s inflammatory social media posts as corroborating evidence of subjective intent to deter rather than litigate.

That preliminary injunction was then reversed by the Seventh Circuit Court of Appeals, which ruled that Florida could proceed with its state-court lawsuit. The appellate court’s ruling does not rehabilitate the factual record Kennelly assembled — his bad-faith findings were based on the preliminary injunction standard, not a final merits determination — but it does mean the Florida litigation is no longer blocked. The procedural posture is now inverted from what most observers expected: the AAP is the federal plaintiff (case number 26-cv-2401, American Academy of Pediatrics v. Uthmeier), while Florida’s original state-court action moves forward in parallel.

Why the Bad-Faith Record Matters

Preliminary injunction rulings are not final judgments, and appellate reversal of an injunction does not mean the lower court was wrong on the facts — only that the legal standard for blocking a parallel state proceeding (governed by the demanding Younger abstention doctrine and its exceptions) was not met. Kennelly’s specific findings — misrepresentation of AAP’s positions, inflammatory public statements, objective weakness of the underlying complaint — remain part of the evidentiary record and will be available to AAP’s lawyers as the litigation continues. They are not erased by the Seventh Circuit’s procedural ruling.

The bad-faith question also intersects with a deeper doctrinal problem for Florida’s theory. The AAP’s policy statement is not a product advertisement; it is a professional society’s published clinical guidance, the kind of speech that has historically received robust First Amendment protection. Applying FDUTPA to that speech requires the court to treat guideline-setting as commercial activity — a theory with no substantial appellate precedent behind it. Florida’s RICO theory faces an even steeper climb: RICO requires a pattern of racketeering activity, predicate criminal acts, and an enterprise structure, none of which map naturally onto the publication of clinical recommendations by a nonprofit medical organization.

A Broader Legal Campaign Against Medical Guideline-Setters

Florida’s lawsuit does not exist in isolation. Since 2022, at least 25 states have introduced legislation restricting access to gender-affirming medical care for minors, with a significant number already enacted into law. Florida itself passed HB935 in 2021 and HB211 in 2022, criminalizing certain gender-affirming procedures for transgender adolescents. The shift from legislative restriction to legal attack on the medical organizations that publish the guidelines underlying such care represents a doctrinal escalation. The Federal Trade Commission, under the Trump administration, separately sued WPATH alongside four states — a parallel campaign that critics and legal observers have characterized as politically coordinated rather than evidence-driven.

The pattern is significant because it tests a novel legal theory at scale: that professional medical associations can be held liable under consumer-protection and racketeering laws for the content of their clinical guidelines. If that theory survives in even one jurisdiction, it creates a mechanism for state governments to use litigation costs and discovery burdens as instruments of medical policy — compelling organizations to revise or retract guidelines not because the science demands it, but because the legal exposure makes continued publication untenable. That is precisely the chilling effect Judge Kennelly identified, and precisely why the First Amendment arguments at the core of AAP’s federal suit carry weight independent of the underlying science.

Major development as appeals court allows Florida's lawsuit against AAP over gender-transition guidance to move forward. This case could have significant implications for medical organizations' liability when… #Florida #MedicalLiability #AAP #Healthcare https://t.co/OJkZ71AL44

— @GlobalRightWatch (@AutonomusRepost) July 11, 2026

What Remains Genuinely Contested

The scientific questions Florida raises — the long-term reversibility of puberty blocker-induced changes, the magnitude of suicidality benefit from gender-affirming interventions, the evidentiary rigor behind clinical guidelines — are not settled with the finality that either side’s litigation posture implies. Systematic reviews from the UK’s Cass Review and analogous European assessments have raised legitimate concerns about the quality of the evidence base for some interventions, even as major American medical societies maintain their endorsements. That scientific debate is real and ongoing. What Florida’s lawsuit does not do is engage that debate scientifically: the complaint cites no peer-reviewed studies, no forensic analysis, and no specific data contradicting the AAP’s claims. It asserts falsity without demonstrating it through the methods by which scientific falsity is actually established.

AAP, for its part, has concentrated its legal response on the First Amendment retaliation theory rather than mounting a point-by-point scientific defense in court filings — a strategically sound choice given that the legal threshold for proving bad faith was lower than the threshold for winning a scientific debate in a courtroom. The result is a litigation record that is legally rich but scientifically thin on both sides, which is precisely the wrong forum for resolving questions about longitudinal patient outcomes and evidence quality. Courts are not peer-review panels, and the Florida complaint’s reliance on legal process to adjudicate scientific disputes is one of its most fundamental structural weaknesses.

What the Seventh Circuit’s Ruling Actually Decides

The appeals court’s decision to allow Florida’s suit to proceed is procedurally significant but substantively limited. It means the state-court case is no longer enjoined — not that Florida’s claims are meritorious, not that the bad-faith record is wrong, and not that FDUTPA or RICO actually reach the publication of clinical guidelines. Those questions will be litigated on the merits, likely over years, with discovery, motions to dismiss, and potentially a trial. The AAP’s federal First Amendment case continues in parallel. The Seventh Circuit’s ruling is, in the most precise sense, a decision about which court gets to decide — not a decision about who is right.

What the case will ultimately test is whether the legal architecture of consumer-protection and racketeering law, built to address commercial fraud, can be repurposed as a tool of medical policy without running afoul of constitutional protections for professional speech. The answer to that question will matter far beyond gender-affirming care — it will define the legal exposure of every medical society that publishes clinical guidelines on any politically contested topic. That is the real stakes of this litigation, and why its resolution deserves attention well past any single news cycle.